Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | CTSC | P53634 | 5/20 | 0.42 |
| ▸ | PRCP | P42785 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | DDOST | P39656 | 1/20 | 0.38 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469380 | 1.00 | DPP7 (0.46) | DPP7CTSCPRCPNOS2NOS3 | |
| SCHEMBL19138319 | 1.00 | DPP7 (0.46) | DPP7CTSCPRCPNOS2NOS3 | |
| SCHEMBL19258205 | 1.00 | DPP7 (0.46) | DPP7CTSCPRCPNOS2NOS3 | |
| Hydrochloric Acid SCHEMBL28600562 | 0.98 | DPP7 (0.45) | DPP7CTSCPRCPNOS2NOS3 | |
| Hydrochloric Acid SCHEMBL28600564 | 0.98 | DPP7 (0.45) | DPP7CTSCPRCPNOS2NOS3 | |
| Hydrochloric Acid SCHEMBL28600561 | 0.98 | DPP7 (0.45) | DPP7CTSCPRCPNOS2NOS3 | |
| SCHEMBL30866235 | 0.89 | DPP7 (0.47) | DPP7CTSCPRCPNOS2NOS3 | |
| SCHEMBL25728331 | 0.89 | DPP7 (0.47) | DPP7CTSCPRCPNOS2NOS3 | |
| SCHEMBL21955441 | 0.89 | DPP7 (0.47) | DPP7CTSCPRCPNOS2NOS3 | |
| SCHEMBL34461082 | 0.86 | DPP7 (0.47) | DPP7CTSCPRCPCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296958-A1 | GLYCOSYLATED CYCLIC ENDOMORPHIN ANALOGS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-09-25 | — | — | US | disclosed |
| EP-4531885-A1 | GLYCOSYLATED CYCLIC ENDOMORPHIN ANALOGS | The Administrators of The Tulane Educational Fund (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2024238396-A1 | NMDA LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| WO-2023235319-A1 | GLYCOSYLATED CYCLIC ENDOMORPHIN ANALOGS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023235232-A2 | GLYCOSYLATED CYCLIC ENDOMORPHIN ANALOGS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2023-12-07 | — | — | WO | disclosed |
| EP-3916003-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | Naurex, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3916003-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | Naurex, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3171941-B1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | NAUREX INC (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3171941-B1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | NAUREX INC (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20180258139-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | NAUREX INC (US) | 2018-09-13 | — | — | US | disclosed |
| US-9994614-B2 | N-methyl-D-aspartate receptor modulators and methods of making and using same | NAUREX, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994614-B2 | N-methyl-D-aspartate receptor modulators and methods of making and using same | NAUREX, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170210779-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | NAUREX INC (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210779-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | NAUREX INC (US) | 2017-07-27 | — | — | US | disclosed |
| WO-2016014982-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | NAUREX, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180258139-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | GRIN1, GRIN2A, GRIN3A | DPP7 1257/4885CTSC 1977/4885PRCP 1950/4885 |
| US-20250296958-A1 | GLYCOSYLATED CYCLIC ENDOMORPHIN ANALOGS | OPRD1, OGFR, OPRL1 | DPP7 256/4885CTSC 562/4885PRCP 1663/4885 |
| US-20170210779-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | GRIN1, GRIN2A, GRIN3A | DPP7 1257/4885CTSC 1977/4885PRCP 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.